FDAnews Announces -- FDA''s New Biosimilars Plan: CBER''s New Policy and the Impact on Pharmaceutical Stakeholders Webinar, Nov. 7, 2018

Thursday, October 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

To date 12 biosimilar products have been approved by the FDA -- but only 3 have reached the market. FDAnews has enlisted the help of consultant Nitisha Pyndiah to spell out what drugmakers need to know: what the FDA is thinking, where the industry is heading, and how to gain competitive advantage.

FALLS CHURCH, Va., Oct. 25, 2018 /PRNewswire-PRWeb/ --FDA's New Biosimilars Plan: CBER's New Policy and the Impact on

Pharmaceutical Stakeholders **An FDAnews Webinar** Nov. 7, 2018 1:30 p.m. 3:00 p.m. ET http://www.fdanews.com/biosimilarsplan

To date 12 biosimilar products have been approved by the FDA but only 3 have reached the market.

The FDA's Biosimilars Action Plan lays out how the agency is modernizing regulatory policies, accommodating new scientific tools to better enable comparison between biosimilars and reference products, and potentially reducing the need for clinical studies.

FDAnews has enlisted the help of consultant Nitisha Pyndiah to spell out what drugmakers need to know: what the FDA is thinking, where the industry is heading, and how to gain competitive advantage. Here are just a few of the specifics to be covered:

  • The key elements of the Biosimilars Action Plan including balancing innovation and competition
  • Interchangeability vs. biosimilarity understanding the differences under the BPCI Act
  • The development and implementation of new FDA review tools (i.e.: standardized review templates tailored to marketing applications for biosimilar and interchangeable products)
  • Enhancements to the Purple Book, including more information about approved biological products
  • The significance of the BsUFA II fees

Drugmakers need to understand the FDA's action plan and how it will affect biosimilar product development. Register today to get an insight into the different stakeholders opinion.

Meet the Presenter: Nitisha Pyndiah Ph.D. is a consultant with HartmannWillner where she provides Biotech Consulting Services to clients, including strategic support for development of biological, biotechnologica, and biosimilar products from preclinical development through the entire product lifecycle.

Who Will Benefit:

  • Executive suite
  • Strategic planners
  • Regulatory affairs
  • QA/QR/QC
  • Manufacturing executives
  • R&D
  • Marketing/sales
  • Legal counsel

Webinar Details: FDA's New Biosimilars Plan: CBER's New Policy and the Impact on Pharmaceutical Stakeholders **An FDAnews Webinar** Nov. 7, 2018 1:30 p.m. 3:00 p.m. ET http://www.fdanews.com/biosimilarsplan

Tuition: $287 per site

Easy Ways to Register: Online: http://www.fdanews.com/biosimilarsplan By phone: 888-838-5578 or 703-538-7600

About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

SOURCE FDANEWS



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store